Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CHINA BIOTECH SERVICES HOLDINGS LIMITED
中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

GRANT OF SHARE AWARDS

Reference is made to the announcement of China Biotech Services Holdings Limited (the "**Company**") dated 18 August 2021 in relation to the share award scheme (the "**Share Award Scheme**") adopted by the Company on 18 August 2021 (the "**Announcement**"). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings ascribed to such terms in the Announcement.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company announces that on 30 March 2026, based on the recommendation of the remuneration committee of the Company (the "**Remuneration Committee**"), the Board has resolved to grant a total of 4,500,000 Award Shares (the "**Grant**"), representing approximately 0.46% of the total issued Shares as at the date of this announcement, to seven selected participants (the "**Grantees**") under the Share Award Scheme at nil consideration, subject to the acceptances by the Grantees. The 4,500,000 Award Shares have been acquired by the Trustee from the open market by utilising the Company's internal resources provided to the Trustee. The 4,500,000 Award Shares represent a market value of HK$3,645,000, by reference to the closing price of HK$0.81 per Share on the date of grant of the Award Shares.

Details of the Grant

The details of the Grant are as follows:

Date of Grant:	30 March 2026
Number of Award Shares granted:	4,500,000
Number of Grantees:	Seven

Consideration for the grant of Award Shares:	Nil
Closing price of the Shares on the date of Grant:	HK$0.81 per Share
Vesting period:	The Award Shares shall vest in the Grantees on the date of the Grant.
Performance target:	There is no performance target attached to the Grant.
Financial assistance:	Nil
Clawback mechanism:	There is no clawback mechanism attached to the Award Shares.
Lock-up period:	The Awarded Shares are subject to a one-year lock-up period upon vesting. During such period, the Grantees shall not directly or indirectly, sell, assign, transfer, permit to exist any lien, donate, give, bequeath, hypothecate or otherwise deal with or dispose of any right or interests in relation to the Awarded Shares in favor of any other person.

The Grantees

Name of Grantees	**Position held with the Group**	**Number of Award Shares**	**Percentage of the Shares in issue as at the date of this announcement**
Mr. Liu Xiaolin ("**Mr. Liu**")	Executive Director and the Chairman of the Company	3,600,000	0.37%
Directors of subsidiaries of the Company		500,000	0.05%
Other employees of the Group		400,000	0.04%
Total		**4,500,000**	**0.46%**

Other than Mr. Liu, an executive Director who is a connected person of the Company and three of the employee participants being directors of certain subsidiaries of the Company, who are connected persons of the Company at the subsidiary level. The grant of Award Shares to each of Mr. Liu and the said three employee participants is a de minimis transaction and is fully exempt from shareholders' approval, annual review and all disclosure requirements under Chapter 20 of the GEM Listing Rules.

Pursuant to Rule 23.04(1) of the GEM Listing Rules, the grant of Award Shares to Mr. Liu has been approved by the independent non-executive Directors. Mr. Liu has abstained from voting on the relevant Board resolutions in respect of the grant of the Award Shares to himself as he has a material interest in the Grant.

Under the Share Award Scheme, which was adopted before the effective date of the new Chapter 23 of the GEM Listing Rules, there are no restrictions prohibiting (a) a vesting period of less than 12 months and (b) the awards granted and to be granted to a Director or chief executive of the Company, or any of their associates in a 12-month period up to and including the date of grant exceeding 0.1% Shares in issue (excluding treasury Shares). To the best of the Directors' knowledge, information and belief having made all reasonable enquires, save as disclosed in this announcement, as at the date of the Grant, (a) none of the other Grantees is a Director, chief executive, or substantial shareholder (as defined under the GEM Listing Rules) of the Company, or an associate (as defined under Chapter 20 of the GEM Listing Rules) of any of them; (b) none of the Grantees is a participant with share options and awards granted and to be granted to him/her within the 12-month period up to and including the date of the Grant exceeding 1% of the Shares in issue (excluding treasury Shares); and (c) none of the Grantees is a related entity participant or service provider with options and awards granted and to be granted in the 12-month period up to and including the date of the Grant exceeding 0.1% of Shares in issue (excluding treasury Shares).

REASONS FOR AND BENEFITS OF THE GRANT

The objectives of the Share Award Scheme are (i) to recognise the contributions by the selected participants; (ii) to offer suitable incentives to attract and retain talented selected participants who may be beneficial to the growth and development of the Group; and (iii) to align the interests of the selected participants directly to the Shareholders through ownership of the Shares, dividends and other distributions paid on the Shares and/or the increase in the value of the Shares.

In considering the grant of the Award Shares to the Grantees with no vesting period, performance target or clawback mechanism attached, the Board and the Remuneration Committee have taken into account the following factors: (a) the past contributions made by the Grantees to the overall business performance and development of the Group; (b) the Grant could effectively align the interests of the Grantees directly with those of the Shareholders through an immediate vesting of the Award Shares; (c) the Grant will provide the Grantees with incentives to continue to contribute to the growth and development of the Group through ownership of the Shares; and (d) in the overall, the Grant can serve the purpose of the Share Award Scheme.

Based on the above, both the Board and the Remuneration Committee are of the view that it is not necessary to set vesting period, performance target and/or clawback mechanism for the grant of the Share Awards to the Grantees.

NUMBER OF SHARES AVAILABLE FOR FUTURE GRANT

After the Grant, 91,241,115 Award Shares will be available for future grant pursuant to the Share Award Scheme. As at the date of this announcement, the Share Award Scheme does not provide for any sublimit on the total number of Award Shares that may be granted to related entities participants or service providers within the scheme mandate limit. The Share Award Scheme was adopted before the effective date of the new Chapter 23 of the GEM Listing Rules. The Company will comply with the new Chapter 23 in accordance with the transitional arrangements provided for the existing share schemes of the Company.

By order of the Board
China Biotech Services Holdings Limited
Chairman and Executive Director
Liu Xiaolin

Hong Kong, 30 March 2026

As at the date of this announcement, the Board comprises four executive Directors, namely, Mr. Liu Xiaolin (Chairman), Mr. He Xun, Dr. Huang Song and Dr. Yin Ye; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Guo Yuantao and Dr. Zhang Xiao.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.